NON-SMALL CELL LUNG CARCINOMA
Clinical trials for NON-SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets rare cancer mutation in 300-Patient trial
Disease control Recruiting nowThis study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated May 26, 2026 03:20 UTC
-
New hope for lung cancer: drug combo trial targets untreated advanced NSCLC
Disease control Recruiting nowThis study tests a new drug, telisotuzumab adizutecan, combined with an immunotherapy (PD-1 inhibitor) for people with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to find the best dose and see if the combination shrinks tumors better than standa…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 26, 2026 03:20 UTC
-
New hope for tough lung cancer: experimental drug faces off against standard chemo
Disease control Recruiting nowThis study tests a new drug, PF-08046054, against the standard chemo docetaxel in people with advanced non-small cell lung cancer that has PD-L1 protein and has stopped responding to prior treatments. About 680 adults will be randomly assigned to one of the two drugs, given as IV…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 03:19 UTC
-
New drug combo aims to reboot immune attack in tough cancers
Disease control Recruiting nowThis study tests a combination of two drugs (retifanlimab and ruxolitinib) in people with advanced lung or kidney cancer whose tumors grew despite prior immunotherapy. The goal is to find the safest dose of ruxolitinib and see if the combo can shrink tumors. About 40 participants…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New drug targets Hard-to-Treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
Inhaled drug mist could boost lung cancer treatment before surgery
Disease control Recruiting nowThis study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC